Interest in the immune tolerance approach for treatment of NMO stems from the fact that the autoimmune response is directed against a well-defined antigen and the anti-AQP4 antibody is simultaneously an effector molecule as well as a biomarker marker of the disease, thereby providing a direct measure of treatment efficacy. The gene discussed is AQP4; the disease is neuromyelitis optica.